United Therapeutics (UTHR) Net Income towards Common Stockholders (2009 - 2026)

United Therapeutics has disclosed Net Income towards Common Stockholders across 18 years of filings, most recently posting $333.0 million for Q2 2026.

• In Q2 2026, Net Income towards Common Stockholders rose 7.59% year-over-year to $333.0 million; the TTM figure through Jun 2026 stood at $1.3 billion (up 5.54% YoY), while the FY2025 annual figure was $1.3 billion, up 11.68% from the prior year.
• Net Income towards Common Stockholders came in at $333.0 million for Q2 2026 at United Therapeutics, up from $274.9 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $364.3 million in Q4 2025 to a low of $116.0 million in Q2 2022.
• Average Net Income towards Common Stockholders over 5 years is $269.4 million, with a median of $276.5 million recorded in 2024.
• The largest YoY upside for Net Income towards Common Stockholders was 747.7% in 2022 against a maximum downside of 32.79% in 2022.
• Over 5 years, Net Income towards Common Stockholders stood at $132.1 million in 2022, then soared by 64.35% to $217.1 million in 2023, then soared by 38.78% to $301.3 million in 2024, then rose by 20.91% to $364.3 million in 2025, then declined by 8.59% to $333.0 million in 2026.
• Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were $333.0 million in Q2 2026, $274.9 million in Q1 2026, and $364.3 million in Q4 2025.